加味半夏白术天麻汤治疗痰湿壅盛型原发性高血压合并高尿酸血症的干预作用被引量：24

Study on Effect of Banxia Baizhu Tianma Decoction on Uric Acid Metabolism in Patients with Phlegm-Damp Accumulation Sydnrome of Hypertension Associated with Hyperuricemia

原文传递

导出

摘要目的:观察加味半夏白术天麻汤治疗痰湿壅盛型原发性高血压病的疗效及其对血尿酸代谢的影响。方法:将60例患者随机分为两组各30例,对照组口服氯沙坦50 mg·d-1;治疗组给予加味半夏白术天麻汤,每天1剂,疗程8周。观察两组的血压及血尿酸变化和不良反应。结果:证候疗效总有效率治疗组89.7%,高于对照组的72.5%(P<0.05)。治疗组治疗后血尿酸水平明显低于治疗前(P<0.01)。治疗后治疗组血尿酸水平明显低于对照组(P<0.05)。结论:加味半夏白术天麻汤对痰湿壅盛型原发性高血压病有较显著的疗效,并能较明显降低血尿酸水平。 Objective： To study the effect of Banxia Baizhu Tianma Decoction on uric acid metabolism in patients with phlegm-damp accumulation sydnrome of hypertension associated with hyperuricemia. Methods： 60 cases with peptic ulcer patients were randomly divided into treatment group and control group and each group contained 30 cases. The treatment group took traditional Chinese medicine Banxia Baizhu Tianma Decoction and the control group was given Losartan. Eight weeks was a course of treatment. The changes in serum level of uric acid and hypertension were observed after treatment by Banxia Baizhu Tianma Decoction for eight weeks. Results： The curative total effective rate was 89. 7% in the treatment group and higher than 71. 4% in the control group（ P〈0. 05）. The treatment group＇s blood uric acid level after treatment was lower than that before treatment（ P〈0. 01）.Treatment group＇s blood uric acid level after treatment was significantly lower than that of the control group（ P〈0. 05）. Conclusion： Banxia Baizhu Tianma Decoction can reduce the blood pressure and it can also decrease the serum level of uric acid.

作者刘树华李彦龙

机构地区甘肃中医学院附属医院甘肃省中医院

出处《辽宁中医杂志》 CAS 北大核心 2015年第1期121-123,共3页 Liaoning Journal of Traditional Chinese Medicine

关键词高血压病痰湿壅盛型中医疗法半夏白术天麻汤血尿酸 hypertension phlegm-damp accumulation sydnrome Banxia Baizhu Tianma Decoction traditional Chinese medicine therapy serum uric acid

分类号 R544.1 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1Breckenridge A.Hypertension and hyperuricaemia[J].Lancet,1966,1:15-18.
2Johnson RJ,Kang DH,Feig D,et al.Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease[J].Hypertension,2003,41:1183-1190.
3Hoieggen A,Alderman MH,Kjeldsem SE,et al.The impact of serum uric acid on cardiovascular outcomes in the LIFE study[J].Kidney Int,2004,65:1041-1049.
4卫生部心血管病防治研究中心.中国高血压防治指南(修订本).高血压杂志,2005,:2-41.
5Rieder MJ,Roman PJ,Greene AS.Reversal of microvascular rarefaction and reduced renal mass hypertension[J].Hypertension,1997,30(11):120-127.
6Johnson RJ.Uric Acid and Diet-Insights into the Epidemic of Cardiovascular Disea se[J].N Engl J Med,2004,350:1071-1073.
7Wurzner G,Gester JG,Chiolero A,et al.Comparative effects of losartan and irbeartan on serum uric acid in hypertensive patients with hyperuricaemia and gout[J].J Hypertens,2001,19:1855-1860.
8Sweet CS,Bradstreet DC,Berman RS,et al.Pharmacodynamic activity of intravenous E-3174,an angiotensinⅡantagonist,inpatients with essential hypertension[J].Am J Hypertens,1994,7:1035-1040.
9Nakashima M,Uematsu T,Kosuge K,et al.Pilot study of the uricosuric effect of Dup-753,a new angiotensinⅡreceptor antagonist,in healthy subjets[J].Eur J Clin Pharmacol,1992,42:333-335.